Literature DB >> 9878020

Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization.

H M Hsu1, C F Lu, S C Lee, S R Lin, D S Chen.   

Abstract

A hepatitis B mass immunization program was launched in Taiwan in July 1984, beginning with newborns of hepatitis B carrier mothers for the first 2 years of the program, which was then extended to all newborns. Seroepidemiology was studied in 3 cohorts at age 6 years. Each cohort consisted of 1500 children proportionally and randomly sampled from those entering elementary school in 1989, 1991, and 1993, representing those born 1 year before the program began and years 1 and 3 of the program, respectively. By RIA, the hepatitis B surface antigen positivity rates in the groups were 10.5%, 6.3%, and 1.7%, respectively; hepatitis B surface antibody positivity rates were 36.9%, 62.0%, 65.4%; and hepatitis B infection rates were 25.0%, 15.9%, 4.3%. Thus, universal immunization was more effective in reducing hepatitis B carriage than selective immunization of newborns of carrier mothers only. The program has proved effective in controlling chronic hepatitis B infection in Taiwan.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9878020     DOI: 10.1086/314585

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited.

Authors:  Jennifer Leong; Derek Lin; Mindie H Nguyen
Journal:  World J Clin Cases       Date:  2016-03-16       Impact factor: 1.337

2.  HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt.

Authors:  Eman Ae Abushady; Magda Ma Gameel; John D Klena; Salwa F Ahmed; Kouka Se Abdel-Wahab; Sanya M Fahmy
Journal:  World J Hepatol       Date:  2011-06-27

3.  Hepatitis B testing and vaccination in immigrants attending English as a second language classes in British Columbia, Canada.

Authors:  T Gregory Hislop; Chris D Bajdik; Chong Teh; Wendy Lam; Shin-Ping Tu; Yutaka Yasui; Roshan Bastani; Vicky M Taylor
Journal:  Asian Pac J Cancer Prev       Date:  2009

Review 4.  Pediatric issues in new therapies for hepatitis B and C.

Authors:  Kathleen B Schwarz
Journal:  Curr Gastroenterol Rep       Date:  2003-06

5.  Clinical features of polyarteritis nodosa in Korea.

Authors:  Young Deok Bae; Hyo Jin Choi; Jung Chan Lee; Jeong Jin Park; Yun Jong Lee; Eun Bong Lee; Yeong Wook Song
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 6.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents.

Authors:  Tzu-Wei Wu; Chen-Chung Chu; Tzu-Ying Ho; Huei-Wen Chang Liao; Sheng-Kai Lin; Marie Lin; Hans Hsienhong Lin; Li-Yu Wang
Journal:  Hum Genet       Date:  2013-06-06       Impact factor: 4.132

8.  Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India.

Authors:  Vijayakumar Velu; Subhadra Nandakumar; Saravanan Shanmugam; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

9.  Essential components in developing public policy to control viral hepatitis: lessons from Taiwan.

Authors:  Jack Wallace; Marian Pitts; Stephen Locarnini; Jeanne Ellard; Marina Carman; Ding-Shinn Chen
Journal:  Hepatol Int       Date:  2015-09-04       Impact factor: 6.047

10.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.